Tag
A novel CGM-derived disposition index reliably estimates beta cell function in individuals with islet autoimmunity without insulin therapy, predicting glycemic deterioration one year later.
This study examines how participant-reported outcomes relate to residual beta cell function and metabolic control in youth newly diagnosed with type 1 diabetes, highlighting modest associations with glucose management but weaker links to be
A randomized cross-over trial reveals that empagliflozin enhances beta cell function and insulin sensitivity more effectively than titrated insulin, suggesting benefits beyond simple glucotoxicity relief.
A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stag
A sub-analysis of the GRADE study reveals that beta-cell function (C-peptide index), rather than alpha-cell responses (glucagon), is the primary driver of glycemic durability in type 2 diabetes across various medication classes, suggesting
Dapagliflozin and exenatide independently improve beta-cell function and insulin sensitivity in type 2 diabetes; their combination markedly enhances these effects, suggesting superior glycemic control potential.
Dynamic C-peptide patterns during OGTT uncover metabolic heterogeneity in GDM, identifying insulin-resistant women at risk for fetal overgrowth and normoglycemic women at risk for preeclampsia, suggesting improved stratified treatment beyon
